RDIF, Hetero agree to produce over 100 mn doses of Sputnik V vaccine in India

Russian Direct Investment Fund (RDIF) and pharma firm Hetero have agreed to produce over 100 million doses per year in India of Sputnik V vaccine against COVID-19, Russia's sovereign wealth fund said in a statement.

parties intend to start production of Sputnik V at beginning of 2021, it added.

Currently Phase III clinical trials are approved and are ongoing in Belarus, UAE, Venezuela and or countries. Phase II-III trials are taking place in India, RDIF said.